NeuroRx Logo.jpg
NeuroRx and Relief Therapeutics Announce Fast Track Designation Granted by the FDA to RLF-100 (Aviptadil) for the Treatment of Respiratory Distress in COVID-19
June 24, 2020 01:30 ET | NeuroRx
Fast Track Designation of RLF-100 for the treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome associated with COVID-19 underscores the urgent need for new treatment options for these...
NeuroRx Logo.jpg
Relief Therapeutics and NeuroRx Expand Clinical Trial of RLF-100 to All Patients with Critical COVID-19 and Respiratory Failure
June 08, 2020 01:00 ET | NeuroRx
Clinical trial expanded to patients treated with both noninvasive and mechanical ventilation in critical COVID-19Clinical trial to enroll 144 patients total with expansion to additional sites RLF-100...